The most played episodes among Podcast App listeners.

1. 1
   Number 1: The Fed Won't Tell You What's Next (3 Stocks to Survive the Storm)

   Get the FREE List of Seven Stocks to Buy and Hold Forever: https://www.marketbeat.com/y/yt984/ Thanks to LifeLock for sponsoring this video. Protect the life you're building with LifeLock. Visit https://lifelock.yt.link/GIaDBpd and use promo code LLSAVE for up to 35% off your first year. Terms apply. The interest rate debate continues as oil prices remain high — is there any hope either comes down soon? MarketBeat analyst Thomas Hughes joins the show to break down why rates are likely staying higher for longer, why oil could spike toward $110-115 before crashing once the conflict in Iran resolves, and three stocks built to handle both. Thomas walks through why the Fed's new chair is deliberately avoiding forward guidance, what that means for investors this year, and three stocks with the balance sheets, pricing power, and reliable cash flow to hold up in this kind of environment — regardless of what rates or oil prices do next. Chapters: 0:00 Introduction 1:06 Interest Rates and the New Fed Chair 2:42 Why Oil Prices Are Staying High 6:29 Stock 1 10:00 Stock 2 13:17 Stock 3 View Bridget's Buys here: https://www.marketbeat.com/bridget 📲 Text 'YouTube' to 68285 for FREE SMS breaking news alerts on top stocks. DISCLAIMER: MarketBeat's videos are for educational and informational purposes only and do not constitute financial, legal, or tax advice. We are not registered investment advisers, and nothing herein is a recommendation to buy, sell, or hold any security or strategy. Investing involves risk—including the potential loss of principal—so always perform your own due diligence and consult a licensed professional before acting. All opinions are those of the presenters and may change without notice. Presenters and MarketBeat personnel may own or trade the securities discussed. Past performance is not indicative of future results; any examples or case studies shown are illustrative and not typical. Some links or promotions mentioned may be affiliate partnerships that compensate MarketBeat at no additional cost to you. MarketBeat and its representatives accept no liability for any losses arising from reliance on this content.

   September 10, 2026·19min
   Play
2. 2
   Number 2: Palantir Just Became Almost Impossible to Replace (This Changes EVERYTHING for the Stock)

   Get Thomas Hughes' FREE list of 7 stocks that could be bigger than today's AI winners: https://www.marketbeat.com/y/yt983/ Palantir just signed a major new deal with the US Army, and MarketBeat analyst Chris Markoch says it's proof the company is becoming nearly impossible to replace. The contract, split with Andoril and coordinated with L3 Harris, entrenches Palantir even deeper as a battlefield system integrator for the US military... and once a company drops Palantir, they lose the entire ontology built on top of it. There's no clean way to walk away. Chris breaks down why the stock jumped roughly 30% after August earnings, what Alex Carp's sovereign AI pitch actually means in practice, and the discounted cash flow math behind Carp's $15-18 billion free cash flow target... including why hitting that number in the next two years could justify Palantir's valuation even if growth slows down after that. We also get into the bull and bear case on Carp as a salesman, why commercial customers who adopt Palantir tend to expand their usage rather than leave, and what this all means for Palantir's next two to ten years. Video Chapters 00:00 Introduction 07:31 The DCF math behind Palantir's valuation 12:25 The new Army contract, explained 19:13 Why Palantir is becoming irreplaceable View Bridget's Buys here: https://www.marketbeat.com/bridget 📲 Text 'YouTube' to 68285 for FREE SMS breaking news alerts on top stocks. DISCLAIMER: MarketBeat's videos are for educational and informational purposes only and do not constitute financial, legal, or tax advice. We are not registered investment advisers, and nothing herein is a recommendation to buy, sell, or hold any security or strategy. Investing involves risk—including the potential loss of principal—so always perform your own due diligence and consult a licensed professional before acting. All opinions are those of the presenters and may change without notice. Presenters and MarketBeat personnel may own or trade the securities discussed. Past performance is not indicative of future results; any examples or case studies shown are illustrative and not typical. Some links or promotions mentioned may be affiliate partnerships that compensate MarketBeat at no additional cost to you. MarketBeat and its representatives accept no liability for any losses arising from reliance on this content.

   September 09, 2026·24min
   Play
3. 3
   Number 3: 3 Critical Materials Stocks Under $20 to Buy Now

   Get the FREE List of the 10 Best AI Infrastructure Stocks Investors Should Be Watching Right Now: https://www.marketbeat.com/y/yt981/ Rare earths and critical materials have had a rough year, and an even rougher last few months. But MarketBeat analyst Chris Markoch says the long-term bull case hasn't changed... the US needs these materials, and needs them to come from home. Right now, all three of these stocks are trading under $20. Chris breaks down USA Rare Earth, Energy Fuels, and Uranium Energy Corp... why each one plays a different role in building out a domestic mine-to-magnet supply chain, how the AI buildout and data center power demand are fueling the uranium story, and why he says this is a multi-year, maybe even multi-decade, story that requires patience. We also cover short interest, dollar cost averaging into volatile names like USA Rare Earth, and why Chris thinks pullbacks like this one can be a buying opportunity for long-term investors. 00:00 Introduction 04:08 Stock 1 14:27 Stock 2 21:54 Stock 3 View Bridget's Buys here: https://www.marketbeat.com/bridget 📲 Text 'YouTube' to 68285 for FREE SMS breaking news alerts on top stocks. DISCLAIMER: MarketBeat's videos are for educational and informational purposes only and do not constitute financial, legal, or tax advice. We are not registered investment advisers, and nothing herein is a recommendation to buy, sell, or hold any security or strategy. Investing involves risk—including the potential loss of principal—so always perform your own due diligence and consult a licensed professional before acting. All opinions are those of the presenters and may change without notice. Presenters and MarketBeat personnel may own or trade the securities discussed. Past performance is not indicative of future results; any examples or case studies shown are illustrative and not typical. Some links or promotions mentioned may be affiliate partnerships that compensate MarketBeat at no additional cost to you. MarketBeat and its representatives accept no liability for any losses arising from reliance on this content.

   September 06, 2026·23min
   Play
4. 4
   Number 4: It's Happening Again: Wall Street Is All In on One Sector (5 Stocks to Buy Now)

   Get the FREE List of the 7 Best Robotic Stocks for Long-Term Growth: https://www.marketbeat.com/y/yt980/ Earnings season just wrapped, and the five most upgraded stocks tracked by MarketBeat all landed in the same sector: cybersecurity. Analyst Thomas Hughes breaks down why agentic AI traffic is driving exponential demand for security across the entire AI stack, and why he believes these companies are positioned to benefit from AI rather than be disrupted by it. Hughes walks through each name's recent earnings results, analyst coverage trends, and price target upside, plus his take on valuations, institutional buying, and where momentum could take these stocks from here. Video Chapters 00:00 Introduction 06:05 Stock 5 09:37 Stock 4 14:22 Stock 3 17:18 Stock 2 21:13 Stock 1 View Bridget's Buys here: https://www.marketbeat.com/bridget 📲 Text 'YouTube' to 68285 for FREE SMS breaking news alerts on top stocks. DISCLAIMER: MarketBeat's videos are for educational and informational purposes only and do not constitute financial, legal, or tax advice. We are not registered investment advisers, and nothing herein is a recommendation to buy, sell, or hold any security or strategy. Investing involves risk—including the potential loss of principal—so always perform your own due diligence and consult a licensed professional before acting. All opinions are those of the presenters and may change without notice. Presenters and MarketBeat personnel may own or trade the securities discussed. Past performance is not indicative of future results; any examples or case studies shown are illustrative and not typical. Some links or promotions mentioned may be affiliate partnerships that compensate MarketBeat at no additional cost to you. MarketBeat and its representatives accept no liability for any losses arising from reliance on this content.

   September 04, 2026·25min
   Play
5. 5
   Number 5: Interest Rates Can't Touch These 3 Stocks (One is Up 540%)

   Get a Special Discount on the Oxford Income Letter: https://www.marketbeat.com/y/yt978/ Drug prices are back in the headlines, but the healthcare and biotech sector has been quietly delivering some of the strongest returns in the market this year, including one name up nearly 500% in a year. Marc Lichtenfeld of the Oxford Club joins the show to break down why healthcare tends to be interest rate neutral and share his top three picks: a short-term technical setup, a mid-term catalyst play, and a long-term dividend growth story. Lichtenfeld covers chart patterns, short interest and squeeze potential, upcoming phase three trial data, and why some biotech names get acquired at massive premiums, plus why blue-chip pharma can offer both growth and reliable dividend increases. Chapters: 00:00 Introduction 02:58 Why Healthcare Is Interest Rate Neutral 06:37 Stock 1 16:29 Stock 2 26:14 Stock 3 Let me know in the comments which of these three picks you're most interested in. 📲 Text 'YouTube' to 68285 for FREE SMS breaking news alerts on top stocks. DISCLAIMER: MarketBeat's videos are for educational and informational purposes only and do not constitute financial, legal, or tax advice. We are not registered investment advisers, and nothing herein is a recommendation to buy, sell, or hold any security or strategy. Investing involves risk—including the potential loss of principal—so always perform your own due diligence and consult a licensed professional before acting. All opinions are those of the presenters and may change without notice. Presenters and MarketBeat personnel may own or trade the securities discussed. Past performance is not indicative of future results; any examples or case studies shown are illustrative and not typical. Some links or promotions mentioned may be affiliate partnerships that compensate MarketBeat at no additional cost to you. MarketBeat and its representatives accept no liability for any losses arising from reliance on this content.

   September 02, 2026·29min
   Play